Facilitating and understanding the family's choice of injection device for growth hormone therapy by using conjoint analysis

Ahmed, S. F.; Smith, W. A.; Blamires, C.
February 2008
Archives of Disease in Childhood;Feb2008, Vol. 93 Issue 2, p110
Academic Journal
Background: Conjoint analysis involves the measurement of consumer preferences between choice alternatives. Aims and objectives: To investigate the use of conjoint analysis in facilitating and understanding choice of growth hormone injection devices. Method and subjects: 56 patients and their parents participated in an electronic, computer-based interview. The interview took a median time of 18 mm (range 12-30) and allowed an immediate matching of injection devices to the family's preferences. Results: Amongst the key drivers of choice, lack of bruising was rated highest and designated an index of 100. Compared to this, the remaining attributes in order of desirability were: auto-injector (98), lack of pain (93), lightweight (88), silent (82), ready-mixed (77), ease of holding (69), telephone helpline (66), needle-free (62), small size (60), nurse support (47), hidden needle (45), stored in fridge (13) and home delivery 161. Out of the 17 families who had already chosen a device previously by discussion with the clinic nurse, the computer model placed their device either as first or second out of seven devices tested. Conclusion: Adaptive or interactive conjoint analysis applied at the patient level can facilitate the choice- making process whilst providing an insight into the relative importance of the key features that influence choice.


Related Articles

  • Monitoring of concordance in growth hormone therapy. Kapoor, A. A.; Burke, S. A.; Sparrow, S. E.; Hughes, I. A.; Dunger, D. B.; Ong, K. K.; Acerini, C. L. // Archives of Disease in Childhood;Feb2008, Vol. 93 Issue 2, p147 

    Concordance with growth hormone (GH) therapy in 75 children was objectively assessed using data on GP prescriptions over 12 months. 23% missed >2 injections! week. Lower concordance was associated with longer duration on GH therapy (p<0.005), lack of choice of delivery device (p<0.005) and short...

  • Measuring the benefits of growth hormone therapy in children: a role for preference-based approaches? Petrou, Stavros; McIntosh, Emma // Archives of Disease in Childhood;Feb2008, Vol. 93 Issue 2, p95 

    The article discusses the importance of growth hormones in addressing growth hormone deficiency in children in Great Britain. It revealed that recombinant human growth hormone revolutionised the management of children with hormonal growth deficiency, chronic renal insufficiency, Turner syndrome,...

  • A Stepwise Increase in Recombinant Human Growth Hormone Dosing During Puberty Achieves Improved Pubertal Growth: A National Cooperative Growth Study Report. Riddick, Linda; Alter, Craig; Davis, D. Aaron; Frane, James; Lippe, Barbara; Bakker, Bert // Journal of Pediatric Endocrinology & Metabolism;Jul2009, Vol. 22 Issue 7, p623 

    The article discusses a study of the near adult height (NAH) improvement of children variedly treated during puberty with increased doses of recombinant human growth hormone (rhGH). It is stated that in patients attaining NAH after three years, an increase of 3.6 centimeters (cm) in mean height...

  • "Anything you can do, I can do bigger?": the ethics and equity of growth hormone for small normal children. Gill, D. G. // Archives of Disease in Childhood;Mar2006, Vol. 91 Issue 3, p270 

    This paper argues against the use of growth hormone (GH) for small normal children (‘idiopathic’ short stature) with the following considerations: ethical (philosophical) grounds, cost-economic implications, and the rationale for treating normal physiological variation with a potent...

  • Growth hormone and mortality: the anatomy of a global scare. Zadik, Zvi // Journal of Pediatric Endocrinology & Metabolism;Jan/Feb2011, Vol. 24 Issue 1/2, p113 

    The article highlights a report of the Santé Adulte GH Enfant (SAGhE) study by the French Agency of Health Safety released in December 2010, which revealed an excess mortality ratio of 93:70 among children treated with recombinant growth hormone (rGH) between 1985 and 1996 compared to other...

  • Can recombinant growth hormone effectively treat idiopathic short stature? Von Fange, Tim; McDiarmid, Todd; Mackler, Leslie // Journal of Family Practice;Sep2008, Vol. 57 Issue 9, p611 

    The article discusses the significance of recombinant human growth hormone (rGH) to treat idiopathic short stature in children in the U.S. It states that injections of rGH at least 3 times a week for 4 to 6 years old add 3.7 to 7.5 centimeters to the final height of children between 8 and 16...

  • Help From A Bug E. coli makes a vital hormone.  // Time;7/30/1979, Vol. 114 Issue 5, p70 

    The article reports on the study conducted by independent teams at the University of California, San Francisco and the commercial research firm Genentech Inc. on genetic engineering technique called recombinant deoxyribonucleic acid (DNA) for the somatotropin production. It mentions that...

  • Idiopathic Short Stature. Lee, Mary M. // New England Journal of Medicine;6/15/2006, Vol. 354 Issue 24, p2576 

    The article presents the case of a 12 year old boy who is below average height for his age and weight. His physical examination is normal, with no signs of puberty, no systemic disease, and no skeletal dysplasia. The author discusses whether growth hormone therapy is indicated. Until recently...

  • Transition of Growth Hormone Treatment: Adolescence to Adulthood. Todorova-Koteva, Kristina I.; Kamboj, Manmohan K. // Current Pediatric Reviews;2009, Vol. 5 Issue 3, p176 

    For patients with childhood-onset growth hormone deficiency, the transition from adolescence to adulthood is a critical phase. A number of studies support the concept that during this transition phase, the adolescent with confirmed severe persistent GHD should continue growth hormone treatment....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics